Dr. Judith A. Dunn Ph.D. is the Pres of R&D and Interim Chief Medical Officer at Fulcrum Therapeutics Inc.
As the Pres of R&D and Interim Chief Medical Officer of Fulcrum Therapeutics Inc, the total compensation of Dr D at Fulcrum Therapeutics Inc is $665,888. There are 3 executives at Fulcrum Therapeutics Inc getting paid more, with Robert Gould having the highest compensation of $3,889,350.
Dr D is 58, he's been the Pres of R&D and Interim Chief Medical Officer of Fulcrum Therapeutics Inc since . There are 6 older and 7 younger executives at Fulcrum Therapeutics Inc. The oldest executive at Fulcrum Therapeutics Inc is Mark J. Levin, 71, who is the Exec. Chairman.
Judith's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk et Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include: